March 14, 2022 Portfolio News from ARCH Venture Partners | Share Nutcracker Therapeutics with Bob Nelsen backing lands $167M to develop its own cancer drugs
March 9, 2022 Portfolio News from ARCH Venture Partners | Share Exclusive: ARCH and GV are building a large startup focused on mitochondrial diseases
February 24, 2022 Portfolio News from ARCH Venture Partners | Share With a new startup, ARCH and Takeda wade into growing search for a Swiss Army knife RNA drug
February 22, 2022 Media Coverage from ARCH Venture Partners | Share Bob Nelsen makes the STAT News 2022 STATUS list. Multiple founders and leaders of ARCH portfolio companies also named, including Jennifer Doudna, Yvonne Greenstreet, Leroy Hood, Daphne Koller and David Liu.
January 20, 2022 Portfolio News from ARCH Venture Partners | Share Super-resolution microscope maker ONI nabs $75M for US expansion, Series B led by ARCH Venture
January 19, 2022 Portfolio News from ARCH Venture Partners | Share With $3 billion, Hal Barron, Bob Nelsen and other biotech veterans launch a disease ‘reversal’ company
January 12, 2022 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Kaye Foster as Venture Partner
December 29, 2021 Media Coverage from ARCH Venture Partners | Share Meet the 28 startups the biggest investor in biotech, ARCH Venture, is betting on this year
December 10, 2021 Media Coverage from ARCH Venture Partners | Share Forbes Healthcare Summit’s Top 10 Leaders of the Decade: Robert Nelsen
December 1, 2021 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Several Key Appointments
October 26, 2021 Portfolio News from ARCH Venture Partners | Share Mozart Therapeutics makes its official debut, jumping into the hot Treg R&D field with ARCH Venture backing it
October 7, 2021 Portfolio News from ARCH Venture Partners | Share ARCH unveils Neumora, its Really Big Neuroscience Company, with $500M, an Amgen deal and eyes on depression, Alzheimer’s and a lot more
